Last reviewed · How we verify
AMT-116 CAR-T cells
AMT-116 CAR-T cells is a Biologic drug developed by Beijing Immunochina Medical Science & Technology Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | AMT-116 CAR-T cells |
|---|---|
| Sponsor | Beijing Immunochina Medical Science & Technology Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMT-116 CAR-T cells CI brief — competitive landscape report
- AMT-116 CAR-T cells updates RSS · CI watch RSS
- Beijing Immunochina Medical Science & Technology Co., Ltd. portfolio CI
Frequently asked questions about AMT-116 CAR-T cells
What is AMT-116 CAR-T cells?
AMT-116 CAR-T cells is a Biologic drug developed by Beijing Immunochina Medical Science & Technology Co., Ltd..
Who makes AMT-116 CAR-T cells?
AMT-116 CAR-T cells is developed by Beijing Immunochina Medical Science & Technology Co., Ltd. (see full Beijing Immunochina Medical Science & Technology Co., Ltd. pipeline at /company/beijing-immunochina-medical-science-technology-co-ltd).
What development phase is AMT-116 CAR-T cells in?
AMT-116 CAR-T cells is in Phase 1.